Kidney cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  NCT04901702· St. Jude Children's Research Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 60
• Machine Learning 70
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening.

  Genes (Basel), Jul 2026

• IDMME and IDMDE: inducible CRISPR-dCasRx platforms for spatiotemporal RNA m5C editing.

  Genome Biol, Jun 2026

• Base editing reveals context-dependent regulation of adhesion, anoikis, and motility by BAP1 in renal cell models.

  Biochem Biophys Res Commun, Jun 2026

• Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer.

  J Clin Invest, Mar 2026

• VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.

  Nat Commun, Mar 2026

• Targeting LncRNAs with CRISPR/Cas9 for Kidney Therapeutics: A Review.

  Int J Biol Macromol, Dec 2025

• Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.

  EMBO Mol Med, Dec 2025

• UBL3 governs VEGFR inhibitor resistance by activating NOTCH signaling in renal cell carcinoma.

  Drug Resist Updat, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.